IRWD News and Press, Ironwood Pharmaceuticals Inc. From 05/25/22

– Other Studies Highlight Impact of Linaclotide in Adult and Pediatric Populations, Highlight Disease Burden – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week &#...

– Data to be featured in two oral presentations and six posters – – CEO Tom McCourt to receive American Society for Gastrointestinal Endoscopy (ASGE) President’s Award at meeting – Ironwood Pharmaceuticals, Inc . (Nasdaq: IRWD), a...

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2022 Earnings Conference Call May 5, 2022 08:30 ET Company Participants Matt Roache - Director, Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Parti...

Ironwood Pharmaceuticals press release (NASDAQ:IRWD): Q1 Non-GAAP EPS of $0.21. Revenue of $98M. FY22 financial guidance maintained. For further details see: Ironwood Pharmaceuticals Non-GAAP EPS of $0.21, revenue of $98M

– LINZESS ® (Iinaclotide) prescription demand growth increased 11% year-over-year; LINZESS U.S. net sales of $232 million, an increase of 8% year-over-year – – Total revenue of $98 million; U.S. LINZESS collaboration revenue of $94 million &...

Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is $0.26 (+8.3% Y/Y) and the consensus Revenue Estimate is $96.62M (+8.7% Y/Y). Over the last 2 years, IRWD has beaten EPS estimates 75% of ...

Positive interim response for appeal of XPHOZAH received for CKD-PH patients; Advisory Committee could possibly turn things around for possible FDA approval. IBSRELA launched commercially in the United States on April 4, 2022; IBS-C market proven with revenues generated by sales of Li...

Piper Sandler has initiated Ironwood Pharmaceuticals (NASDAQ:IRWD) at overweight citing the success of the company's irritable bowel syndrome drug Linzess (linaclotide). The firm has a $16 price target (~36% upside based on Thursday's close). Analyst David Amsellem said that Linzess has three...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 5, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and ...

PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...